{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:52:37Z","timestamp":1790646757017,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The four-component serogroup B meningococcal 4CMenB vaccine (\n                      <jats:italic>Bexsero<\/jats:italic>\n                      , GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12\u00a0months of age since September 2015. After 3\u00a0years, Public Health England (PHE) reported a 75% [95% confidence interval 64%; 81%] reduction in the incidence of serogroup B invasive meningococcal disease (IMD) in age groups eligible to be fully vaccinated. In contrast, vaccine effectiveness (VE) evaluated in the same immunization program applying the screening method was not statistically significant. We re-analyzed the data using an incidence model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Aggregate data\u2014stratified by age, year and doses received\u2014were provided by PHE: serogroup B IMD case counts for the entire population of England (years 2011\u20132018) and 4CMenB vaccine uptake in infants. We combined uptake with national population estimates to obtain counts of vaccinated and unvaccinated person-time by age and time. We re-estimated VE comparing incidence rates in vaccinated and non-vaccinated subjects using a Bayesian Poisson model for case counts with person-time data as an offset. The model was adjusted for age, time and number of doses received.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence model showed that cases decreased until 2013\u20132014, followed by an increasing trend that continued in the non-vaccinated population during the immunization program. VE in fully vaccinated subjects (three doses) was 80.1% [95% Bayesian credible interval (BCI): 70.3%; 86.7%]. After a single dose, VE was 33.5% [12.4%; 49.7%]\n                      <jats:sub>95%BCI<\/jats:sub>\n                      and after two doses, 78.7% [71.5%; 84.5%]\n                      <jats:sub>95%BCI<\/jats:sub>\n                      . We estimated that vaccination averted 312 cases [252; 368]\n                      <jats:sub>95%BCI<\/jats:sub>\n                      between 2015 and 2018. VE was in line with the previously reported incidence reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our estimates of VE had higher precision than previous estimates based on the screening method, which were statistically not significant, and in line with the 75% incidence reduction previously reported by PHE. When disease incidence is low and vaccine uptake is high, the screening method applied to cases exclusively from the population eligible for vaccination may not be precise enough and may produce misleading point-estimates. Precise and accurate VE estimates are fundamental to inform public health decision making. VE assessment can be enhanced using models that leverage data on subjects not eligible for vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06906-x","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T15:02:28Z","timestamp":1639234948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-068X","authenticated-orcid":false,"given":"Lorenzo","family":"Argante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Abbing-Karahagopian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Vadivelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"issue":"9580","key":"6906_CR1","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196\u2013210. https:\/\/doi.org\/10.1016\/S0140-6736(07)61016-2.","journal-title":"Lancet"},{"issue":"1","key":"6906_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","volume":"18","author":"R Acevedo","year":"2019","unstructured":"Acevedo R, Bai X, Borrow R, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15\u201330. https:\/\/doi.org\/10.1080\/14760584.2019.1557520.","journal-title":"Expert Rev Vaccines"},{"issue":"123","key":"6906_CR3","doi-asserted-by":"publisher","first-page":"123ps5-123ps5","DOI":"10.1126\/scitranslmed.3003859","volume":"4","author":"S Black","year":"2012","unstructured":"Black S, Pizza M, Nissum M, Rappuoli R. Toward a meningitis-free world. Sci Transl Med. 2012;4(123):123ps5-123ps5. https:\/\/doi.org\/10.1126\/scitranslmed.3003859.","journal-title":"Sci Transl Med"},{"issue":"3","key":"6906_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/erv.10.3","volume":"9","author":"A Khatami","year":"2010","unstructured":"Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9(3):285\u201398. https:\/\/doi.org\/10.1586\/erv.10.3.","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"6906_CR5","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","volume":"15","author":"S Sridhar","year":"2015","unstructured":"Sridhar S, Greenwood B, Head C, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334\u201346. https:\/\/doi.org\/10.1016\/S1473-3099(15)00217-0.","journal-title":"Lancet Infect Dis"},{"key":"6906_CR6","unstructured":"European Medicines Agency. Bexsero. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bexsero. Accessed 3 Aug 2020."},{"issue":"6","key":"6906_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307\u201326.","journal-title":"J Exp Med"},{"issue":"10061","key":"6906_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","volume":"388","author":"SR Parikh","year":"2016","unstructured":"Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(16)31921-3.","journal-title":"Lancet"},{"issue":"4","key":"6906_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","volume":"382","author":"SN Ladhani","year":"2020","unstructured":"Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1901229.","journal-title":"N Engl J Med"},{"issue":"6","key":"6906_CR10","first-page":"1055","volume":"63","author":"WA Orenstein","year":"1985","unstructured":"Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63(6):1055\u201368.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"6906_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ije\/22.4.742","volume":"22","author":"CP Farrington","year":"1993","unstructured":"Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22(4):742\u20136. https:\/\/doi.org\/10.1093\/ije\/22.4.742.","journal-title":"Int J Epidemiol"},{"key":"6906_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-68636-3","volume-title":"Design and analysis of vaccine studies: introduction","author":"ME Halloran","year":"2009","unstructured":"Halloran ME, Longini IM Jr, Struchiner CJ. Design and analysis of vaccine studies: introduction. Berlin: Springer; 2009. https:\/\/doi.org\/10.1007\/978-0-387-68636-3."},{"issue":"2","key":"6906_CR13","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S2468-2667(17)30234-7","volume":"3","author":"G Amirthalingam","year":"2018","unstructured":"Amirthalingam G, Andrews N, Keel P, et al. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 2018;3(2):e82\u201390. https:\/\/doi.org\/10.1016\/S2468-2667(17)30234-7.","journal-title":"Lancet Public Health"},{"key":"6906_CR14","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2008.","edition":"3"},{"key":"6906_CR15","doi-asserted-by":"crossref","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis. 3rd edition. Taylor & Francis; 2013. https:\/\/books.google.it\/books?id=ZXL6AQAAQBAJ.","DOI":"10.1201\/b16018"},{"issue":"479","key":"6906_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1198\/016214506000001040","volume":"102","author":"A Gelman","year":"2007","unstructured":"Gelman A, Fagan J, Kiss A. An analysis of the New York City police department\u2019s \u201cstop-and- frisk\u201d policy in the context of claims of racial bias. J Am Stat Assoc. 2007;102(479):813\u201323. https:\/\/doi.org\/10.1198\/016214506000001040.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"6906_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1191\/1740774504cn025oa","volume":"1","author":"H Chu","year":"2004","unstructured":"Chu H, Halloran ME. Bayesian estimation of vaccine efficacy. Clin Trials. 2004;1(3):306\u201314. https:\/\/doi.org\/10.1191\/1740774504cn025oa.","journal-title":"Clin Trials"},{"key":"6906_CR18","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.7717\/peerj-cs.55","volume":"2","author":"J Salvatier","year":"2016","unstructured":"Salvatier J, Wiecki TV, Fonnesbeck C. Probabilistic programming in Python using PyMC3. PeerJ Comput Sci. 2016;2:e55. https:\/\/doi.org\/10.7717\/peerj-cs.55.","journal-title":"PeerJ Comput Sci"},{"issue":"4","key":"6906_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7(4):457\u201372. https:\/\/doi.org\/10.1214\/ss\/1177011136.","journal-title":"Stat Sci"},{"issue":"26","key":"6906_CR20","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","volume":"36","author":"SR Parikh","year":"2018","unstructured":"Parikh SR, Campbell H, Gray SJ, et al. Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010\u20132015. Vaccine. 2018;36(26):3876\u201381. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.038.","journal-title":"Vaccine"},{"issue":"1","key":"6906_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-016-0642-2","volume":"14","author":"L Argante","year":"2016","unstructured":"Argante L, Tizzoni M, Medini D. Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines. BMC Med. 2016;14(1):1\u201314. https:\/\/doi.org\/10.1186\/s12916-016-0642-2.","journal-title":"BMC Med"},{"issue":"oct09 4","key":"6906_CR22","doi-asserted-by":"publisher","first-page":"g5725","DOI":"10.1136\/bmj.g5725","volume":"349","author":"H Christensen","year":"2014","unstructured":"Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349(oct09 4):g5725\u2013g5725. https:\/\/doi.org\/10.1136\/bmj.g5725.","journal-title":"BMJ"},{"issue":"47","key":"6906_CR23","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","volume":"38","author":"E Beck","year":"2020","unstructured":"Beck E, Klint J, Garcia S, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38(47):7558\u201368. https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.007.","journal-title":"Vaccine"},{"issue":"5","key":"6906_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","volume":"13","author":"U Vogel","year":"2013","unstructured":"Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(13)70006-9.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"6906_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","volume":"17","author":"SR Parikh","year":"2017","unstructured":"Parikh SR, Newbold L, Slater S, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment. Lancet Infect Dis. 2017;17(7):754\u201362. https:\/\/doi.org\/10.1016\/S1473-3099(17)30170-6.","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"6906_CR26","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","volume":"33","author":"D Medini","year":"2015","unstructured":"Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629\u201336. https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.015.","journal-title":"Vaccine"},{"issue":"3","key":"6906_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8030469","volume":"8","author":"C Azzari","year":"2020","unstructured":"Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4cmenb vaccine against group b meningococcal disease in two italian regions using different vaccination schedules: a five-year retrospective observational study (2014\u20132018). Vaccines. 2020;8(3):1\u201312. https:\/\/doi.org\/10.3390\/vaccines8030469.","journal-title":"Vaccines"},{"issue":"21","key":"6906_CR28","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1001\/jama.2020.20449","volume":"324","author":"FMP Rodrigues","year":"2020","unstructured":"Rodrigues FMP, Marlow R, Sim\u00f5es MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187. https:\/\/doi.org\/10.1001\/jama.2020.20449.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06906-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T15:04:48Z","timestamp":1639235088000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06906-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6906"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06906-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-493163\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"18 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used epidemiological data aggregated at the country level and therefore did not require an ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lorenzo Argante, Victoria Abbing-Karahagopian, Kumaran Vadivelu and Rino Rappuoli are employed by the GSK group of companies and declare financial and non-financial conflicts of interest. Duccio Medini was employed by the GSK group of companies at the time of the study and declares financial and non-financial conflicts of interest. Kumaran Vadivelu, Rino Rappuoli and Duccio Medini also hold shares in the GSK group of companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1244"}}